5.39
-2.3865(-30.67%)
Currency In USD
| Previous Close | 7.78 |
| Open | 5.91 |
| Day High | 5.91 |
| Day Low | 4.61 |
| 52-Week High | 18.55 |
| 52-Week Low | 4.61 |
| Volume | 491,893 |
| Average Volume | 337,013 |
| Market Cap | 140.54M |
| PE | -2.04 |
| EPS | -2.65 |
| Moving Average 50 Days | 9.93 |
| Moving Average 200 Days | 11.39 |
| Change | -2.39 |
If you invested $1000 in CVRx, Inc. (CVRX) since IPO date, it would be worth $192.63 as of May 09, 2025 at a share price of $5.394. Whereas If you bought $1000 worth of CVRx, Inc. (CVRX) shares 3 years ago, it would be worth $1,029.29 as of May 09, 2025 at a share price of $5.394.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025
GlobeNewswire Inc.
Apr 24, 2025 8:30 PM GMT
MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that it plans to release first quarter 2025 financial and operating results after market close on Thursda
CVRx Reports Preliminary First Quarter 2025 Financial Results
GlobeNewswire Inc.
Apr 07, 2025 8:05 PM GMT
First quarter revenue expected to be approximately $12.3 million, representing growth of approximately 15% over first quarter 2024MINNEAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device
CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim
GlobeNewswire Inc.
Feb 12, 2025 7:45 PM GMT
New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstrates large and statistically significant reductions in hospital visits and length of stay in patients with heart failure and re